Ukraine’s pharmaceutical industry can strengthen its position in Europe by developing production of active pharmaceutical ingredients. The government views this segment as a way to reduce dependence on imported raw materials and to build joint manufacturing chains with European Union companies.
Deputy Prime Minister for European and Euro-Atlantic Integration Taras Kachka said Ukraine should pay special attention to active ingredient production because it can connect Ukrainian and European manufacturers in a single pharmaceutical value chain. In his view, Ukrainian producers are not a threat to EU companies, but potential partners that can increase European competitiveness globally.
Standards as investment
The strategy also changes how businesses should view EU regulation. Requirements such as good manufacturing practice, two-dimensional coding and other quality standards may create costs, but they also push modernization and make production more credible for foreign partners.
For Ukrainian companies, the opportunity is medium term. Harmonization with EU rules can open access to a larger market, while local production of ingredients can protect the sector from supply disruptions. This is especially important when global pharmaceutical chains remain sensitive to logistics, regulation and price shocks.
If Ukraine builds reliable ingredient production, it could move from being mainly a finished-medicine market to a deeper participant in European pharmaceutical manufacturing. That would support exports, industrial investment and a more resilient healthcare supply chain.
